1-4 of 4
Takashi Yoshida
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Interleukin-7 Risk Allele, Lymphocyte Counts, and Autoantibodies for Prediction of Risk of Immune-Related Adverse Events in Patients Receiving Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma

Available to Purchase
Subject Area:
Oncology
Hitomi Takada, Leona Osawa, Yasuyuki Komiyama, Masaru Muraoka, Yuichiro Suzuki, Mitsuaki Sato, Shoji Kobayashi, Takashi Yoshida, Shinichi Takano, Shinya Maekawa, Nobuyuki Enomoto
Journal: Oncology
Oncology (2025) 103 (1): 37–47.
https://doi.org/10.1159/000540648
Published Online: 30 July 2024
View articletitled, Interleukin-7 Risk Allele, Lymphocyte Counts, and Autoantibodies for Prediction of Risk of Immune-Related Adverse Events in Patients Receiving Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma
Open the PDF for Interleukin-7 Risk Allele, Lymphocyte Counts, and Autoantibodies for Prediction of Risk of Immune-Related Adverse Events in Patients Receiving Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma in another window
Journal Articles

Relationship between Plasma IP-10/CXCL10 Levels and the Initial Therapeutic Response in Patients Treated with Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma

Available to Purchase
Subject Area:
Karger e-Journal Backfile Collection 2023 , Oncology
Hitomi Takada, Koji Yamashita, Leona Osawa, Yasuyuki Komiyama, Natsuko Nakakuki, Masaru Muraoka, Yuichiro Suzuki, Mitsuaki Sato, Shoji Kobayashi, Takashi Yoshida, Shinichi Takano, Shinya Maekawa, Nobuyuki Enomoto
Journal: Oncology
Oncology (2023) 101 (10): 655–663.
https://doi.org/10.1159/000531689
Published Online: 28 June 2023
View articletitled, Relationship between Plasma IP-10/CXCL10 Levels and the Initial Therapeutic Response in Patients Treated with Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma
Open the PDF for Relationship between Plasma IP-10/CXCL10 Levels and the Initial Therapeutic Response in Patients Treated with Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma in another window
Journal Articles

Application of Bromodeoxyuridine (BrdU) and Anti-BrdU Monoclonal Antibody for the in vivo Analysis of Proliferative Characteristics of Human Leukemic Cells in Bone Marrows

Available to Purchase
Subject Area:
Oncology
Shinobu Nakamura, Yasushi Takeda, Masatoshi Kanno, Takashi Yoshida, Shigeki Ohtake, Kazumi Kobayashi, Yohko Okabe, Tamotsu Matsuda
Journal: Oncology
Oncology (1991) 48 (4): 285–289.
https://doi.org/10.1159/000226944
Published Online: 26 June 2009
View articletitled, Application of Bromodeoxyuridine (BrdU) and Anti-BrdU Monoclonal Antibody for the in vivo Analysis of Proliferative Characteristics of Human Leukemic Cells in Bone Marrows
Open the PDF for Application of Bromodeoxyuridine (BrdU) and Anti-BrdU Monoclonal Antibody for the in vivo Analysis of Proliferative Characteristics of Human Leukemic Cells in Bone Marrows in another window
Journal Articles

Treatment of Myelodysplastic Syndromes with Orally Administered l-β-Z)-Arabinofuranosylcytosine-5’-Stearylphosphate

Available to Purchase
Subject Area:
Oncology
Ryuzo Ohno, Noriyuki Tatsumi, Masami Hirano, Kuniyuki Imai, Hideaki Mizoguchi, Tohru Nakamura, Masaaki Kosaka, Kiyoshi Takatsuki, Toshihiko Yamaya, Keisuke Toyama, Takashi Yoshida, Tohru Masaoka, Shuji Hashimoto, Toshiteru Ohshima, Ikuro Kimura, Kazumasa Yamada, Kiyoji Kimura
Journal: Oncology
Oncology (1991) 48 (6): 451–455.
https://doi.org/10.1159/000226979
Published Online: 26 June 2009
View articletitled, Treatment of Myelodysplastic Syndromes with Orally Administered l-β-Z)-Arabinofuranosylcytosine-5’-Stearylphosphate
Open the PDF for Treatment of Myelodysplastic Syndromes with Orally Administered l-β-Z)-Arabinofuranosylcytosine-5’-Stearylphosphate in another window